Association of p53 expression with second primary tumour development in hypopharyngeal carcinoma

Journal of Laryngology and Otology

Volumn 114, Issue 3, 2000, Pages 198-201

  Hattori, Kenji ^a,c   Inohara, Hidenori ^a   Sawada, Toru ^a   Honjo, Yuichiro ^b   Yoshida, Jun Ichi ^b   Kubo, Takeshi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Osaka Teishin Hospital   (Japan)

^c SUMITOMO HOSPITAL   (Japan)

Author keywords

Carcinoma; Hypopharynx; Neoplasms; Protein p53; Second primary; Squamous cell

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

CANCER RECURRENCE; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; MALE; PROTEIN EXPRESSION; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

EID: 0034111518     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1258/0022215001905328     Document Type: Conference Paper

References (22)

1. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989:244:217-21
2. Kastan MB, Onyekwere O, Sidransky D, Vogelsteine B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11
3. Yin Y, Tainsky MA, Bishoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992:70:937-48
4. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:786-7
5. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumour-suppressor gene in clinical oncology. J Clin Oncol 1995:13:1009-22
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78
7. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, et al, Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma, Virchows Arch 1993;422:271-6
8. Watanabe S, Yamaguchi N, Kinjo Y. History and overview of the site-specific cancer registries in Japan. Gann Monogr Cancer Res 1995;43:1-8
9. Ishikawa N, Hentona H, Sugimoto T, Haraguchi H, Komatsuzaki A. Clinical analysis of hypopharyngeal carcinoma. Jpn Bronchoesophagol Soc 1996;47:1-8
10. Warren S, Gates O. Multiple primary malignant tumors: a survey of literature and statistical study. Am J Cancer 1932;16:1358-1414
11. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 1992;71:587-97
12. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al. p53 tumour suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6
13. Hong WK, Bromer RH, Amato DA, Shapshay S, Vincent M, Vaughan C, et al. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985;56:1242-5
14. Wynder EL, Mushinsk MH, Spivac JC. Tobacco and alcohol consumption in relation to the development of multiple primary cancers. Cancer 1997;40:1872-8
15. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. New Engl J Med 1995;332:712-7
16. Calzolari A, Chiarelli I, Bianchi S, Messerini L, Gallo O, Porfirio B, et al. Immunohistochemical vs molecular biology methods: complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997;107:7-11
17. Nylander K, Nilsson P, Mehle C, Roos G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995;71:826-30
18. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25
19. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 as induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994:54:1169-74
20. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992:70:923-35
21. Momand J, Zambetti G, Olson DC, George D, Levine AI. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45
22. Girod SC, Cesarz D, Fischer U, Krueger GR. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res 1995;15:1453-7